Background and Objectives: A variety of demographic factors, sex, and degree of immunosuppression can influence antiretroviral drug concentrations. The authors studied the influence of immune status, sex, and body mass index (BMI) on the steady-state pharmacokinetics of nevirapine delivered as a fixed-dose combination in HIV-1-infected patients in India. Methods: Twenty-six HIV-1-infected adult patients undergoing treatment with nevirapine-based highly active antiretroviral therapy regimens participated in the study. Pharmacokinetic variables were compared between patients divided based on CD4 cell counts, sex, and BMI. Results: Patients with higher BMI had lower peak and trough concentration and exposure of nevirapine than those with lower BMI; none of the differences in the pharmacokinetic variables of nevirapine between the various patient groups was statistically significant. Conclusions: Patients' immune status, sex, or BMI had no impact on the pharmacokinetics of nevirapine. Plasma nevirapine concentrations were maintained within the therapeutic range of the drug in the majority of the patients.
World Health Organization.Scaling Up Antiretroviral Therapy in Resource Limited Settings: Treatment Guidelines for a Public Health Approach—2003 Revision. Geneva: World Health Organization; 2003. Available at: http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf .
2.
Kumarasamy N. , Solomon S., Chaguturu SK, et al. The changing natural history of HIV disease: before and after the introduction of generic antiretroviral therapy in Southern India. Clin Infect Dis.2005;41:1525-1528.
3.
Calmy A., Pinoges L., Szumilin E., et al. Generic fixed dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20: 1163-1169.
4.
Laurent C., Kouanfack C., Koulla-Shiro S., et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004 ;364:29-34.
5.
Pujari SN, Patel AK, Naik E., et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immun Defic Syndr. 2004;37:1566-1569.
6.
Phair JP, Flexner CWFactors Associated With Pharmacokinetic Variability in HIV-Infected Patients . Chicago, IL: Northwestern University, Feinberg School of Medicine, Office of Continuing Medical Education, iMedOptions ; 2004.
7.
La Porte C., Burger D., Gyssens I., Sprenger H., Koopman P.Gender differences in Nevirapine pharmacokinetics, fact or fiction?Program and abstracts of the 4th International Workshop on Clinical Pharmacology in HIV therapy; 2003; France.
8.
Keating J., Bjarnason I., Somasundaram S., et al. Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhea. Gut. 1995;37:623-629.
9.
Moyer TP, Temesgen Z., Enger R., et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem.1999;45:1465-1476.
10.
National Institute of Nutrition (Indian Council of Medical Research).Hyderabad, India, 2005.
11.
Kappelhoff BS, van Leth F., Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations?Antivir Ther.2005;10:489-498.
12.
Donnerer J. , Kronawetter M., Kapper A., Haas I., Kessler HHTherapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. Pharmacology. 2003;69:197-204.
13.
Havlir D., Cheeseman SH, McLaughlin M., et al. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis.1995;171:537-545.
14.
Hosseinipour MC, Corbett A., Kanyama C., et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian subjects. 12th Conference in Retroviruses and Opportunistic Infections; 2005; Boston .
15.
van Heeswijk RPG , Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1 infected individuals . AIDS. 2000;14:F77-F82.
16.
van Praag RME , van Weert ECM, van Heeswijk RPG, et al. Stable concentrations of zidovudine, stavudine, lamivudine, abacavir and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother.2002;46: 896-899.
17.
Ribera E., Pou L., Lopez RM, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immun Defic Syndr. 2001;28:450-453.
18.
de Maat MM, Huitema AD, Mulder JW, Meenhorst PC, van Gorp EC, Beijnen JHPopulation pharmacokinetics of nevirapine in an unselected cohort of HIV-1 infected individuals. Br J Clin Pharmacol.2002;54:378-385.
19.
Gurumurthy P., Ramachandran G., Hemanth Kumar AK, et al. Decreased bioavailability of rifampin and other anti-TB drugs in patients with advanced HIV disease. Antimicrob Agents Chemother.2004;48:4473-4475.
